Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure
NCT ID: NCT05652322
Last Updated: 2025-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2/PHASE3
INTERVENTIONAL
2022-12-07
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
NCT00904488
Combination Diuretic Therapy for Acute Decompensated Heart Failure
NCT05840536
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
NCT05093621
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
NCT06024889
Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure
NCT00355667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
prolonged intravenous loop diuretic treatment - furosemide
Furosemide Injection
change from intravenous to oral furosemide
Group 2
Early (48 hrs) change to oral loop diuretic - furosemide - 150% eqivalent iv dose
Furosemide Pill 150% equivalent iv dose
change from intravenous to oral furosemide
Group 3
Early (48 hrs) change to oral loop diuretic - furosemide - 200% eqivalent iv dose
Furosemide Pill 200% equivalent iv dose
change from intravenous to oral furosemide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Furosemide Pill 150% equivalent iv dose
change from intravenous to oral furosemide
Furosemide Pill 200% equivalent iv dose
change from intravenous to oral furosemide
Furosemide Injection
change from intravenous to oral furosemide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Fluid Retention Features:
* Described congestion above the lung fields on chest X-ray
* rales on chest auscultation
* Peripheral edema, yielding to pressure occurring within the limbs or the sacral part of the spine
* Increased pressure in the jugular veins (\>=8 cm H2O)
2. The concentration of natiuretic peptides must be assessed within 24 hours of admission to the hospital and be:
✔ NTpro-BNP \>450 pg/mL for \<55 years, 900 pg/mL for 55-75 years, and \>1800 pg/mL for \>75 years
3. Exacerbation of heart failure treated with at least 40 mg of furosemide IV. (or 20 mg torasemide equivalent)
4. Left ventricular ejection fraction \< 50% (assessed and documented in the last 12 months prior to study entry)
5. Age \>= 18 years
6. The study participant gave and signed an informed consent to participate in the study. No medical procedure related to the study was performed prior to giving informed consent.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jan Kochanowski University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zbigniew Siudak
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janusz Sielski, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Jan Kochanowski Univeristy in Kielce
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wojewodzki Szpital Zespolony Klinika Nefrologii
Kielce, , Poland
Wojewódzki Szpital Zespolony OIOK
Kielce, , Poland
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Oddzial Kardiologii
Lodz, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Jan Kochanowski University Kielce, Poland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1/KCW/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.